

Innovation Framework

Ideation

Ideas we believe in

The general situation

The circumstances the world is in

- Obesity is a growing driver of colossal health & economic burden globally
- Current management is ineffective & too expensive
- Discovery of GLP-1RAs has opened new opportunities
- · Current market is dominated by a duopoly
- Disruptive innovation is an attractive opportunity

Purpose

Reduce the physical, emotional & economic burdens of obesity—thereby creating value for all stakeholders

Capabilities that matter

- Disruptive innovation
- Efficient, multidisciplinary evidence generation
- Low-cost high-scale manufacturing
- Delivering great consumer experiences

Vision

Consumers – particularly those with health risk from obesity - have a great experience losing weight, sustaining it and improving their lives at affordable cost long term

Quality

• We care & our stakeholders & partners experience that caring

Goals by 2050

- Reverse or prevent 5M cases of T2DM
- Reduce 25 million life years lost per year
- Reduce direct health costs by \$100B
- While generating \$50B shareholder value

Identity

• We are empathetic, data-driven, disruptive & trustworthy

consumers & other stakeholders

Measure impact with customers

Manage change

Core Business Process

How we intend to create value

Identify needs

What is the job to be done?

- Reduce obesity-inducing intake
- Change life-long behaviors

What are the specific innovation opportunities?

- Reduced disutility
- Scaling

What is the customer (including consumer) value proposition?

• Better life (tbd)

Develop solutions

- Easier to use
- More tolerable
- Just as or more effective
- Lower cost

Search for & secure technology

- GLP-1RA & combinations
- Long acting
- Oral delivery
- Lowest possible COGs

Generate evidence with customers

• Efficient data generation

- Iterate core business process

& consumers & other stakeholders

- Stakeholder participation

Strategy

What we choose to focus on

	Specific situation	Main choices	Action plans
Competitive	Massive global market Growing Wegovy / Mounjaro Scale & cost of goods matter Duopoly (others entering) Activated consumers Defensive payers	Global strategy day-1 Benchmark everything Low PPE investment Disruptive innovation Consumer-centric Partner with payers	Develop multiple products Super-efficient evidence generation. Manufacture via partners Attack disutility Execute consumer launch Engage payers up-front
Human	Biopharma + consumerism Lifelong consumer quest	Multidisciplinary talent Provide lifelong engagement	Recruit & empower diversity Create compelling experience
Financial	Capital intensive Risk of dilution Challenging financing environment	Build leading syndicates Tranche with value step-ups Access public markets early	Active constant engagement Well-timed financings Run it like its already public
Communications	High-volume major current coverageEarly days	Measured messages until PoCDifferentiated identityHighly selective engagement	Audience-driven approach Focus on investors

with curated audiences

• Crowded pipeline